Liting Wang

Hainan Institute of Biotechnology, Haikou, 570206, Hainan, China
Author    Correspondence author
International Journal of Clinical Case Reports, 2024, Vol. 14, No. 5   
Received: 13 Jul., 2024    Accepted: 19 Aug., 2024    Published: 18 Sep., 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study explores the genetic mechanisms and clinical significance of HPV16- and HPV18-specific variants in cervical cancer. Studies have shown that different variants of HPV16 and HPV18 exhibit significant differences in oncogenic potential, manifested through gene mutations, integration patterns, and interactions with the host genome. These variants primarily promote carcinogenesis by altering the functions of viral proteins, such as E6 and E7, which impact cell cycle regulation, DNA damage repair, and immune evasion mechanisms. Furthermore, specific variants of HPV16 and HPV18 display distinct geographical and population distributions, potentially influencing the epidemiological characteristics of cervical cancer in various regions. Understanding the oncogenic mechanisms and distribution patterns of these variants is crucial for developing personalized diagnostic tools, therapeutic strategies, and effective vaccines. Future research should focus on new variant types, the integration of genomics and immunotherapy, and the development of next-generation vaccines to better manage and prevent cervical cancer and reduce the disease burden.

HPV16; HPV18; Cervical cancer; Genetic variants; Personalized medicine